Oncozene
Payments companies reported to CMS as associated with Oncozene. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Oncozene, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Oncozene
These are the largest totals companies reported as associated with Oncozene. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Mohammad Ali | Mishawaka, IN | Vascular & Interventional Radiology | $150.81 |
| Maziar Sighary | Brooklyn, NY | Vascular & Interventional Radiology | $150.81 |
| Kathryn Parvin | Jackson, MS | Vascular & Interventional Radiology | $140.41 |
| James Thomasson | Jackson, MS | Vascular & Interventional Radiology | $140.41 |
| Mohammed Hoque | Las Vegas, NV | Vascular & Interventional Radiology | $134.73 |
| Shamail Butt | Chicago, IL | Hematology & Oncology | $134.73 |
| David Sada | Houston, TX | Diagnostic Radiology | $121.81 |
| Tust Techasith | Stanford, CA | Diagnostic Radiology | $84.50 |
| Trushar Patel | Newport Beach, CA | Vascular & Interventional Radiology | $84.50 |
| Greyson Mcgowin | Birmingham, AL | Diagnostic Radiology | $83.66 |
Prescribed Oncozene?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.